Qiagen (NYSE:QGEN – Get Free Report) issued an update on its third quarter 2026 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of 0.650-0.650 for the period, compared to the consensus EPS estimate of 0.620. The company issued revenue guidance of $548.0 million, compared to the consensus revenue estimate of $534.1 million.
Wall Street Analysts Forecast Growth
Several research analysts recently commented on QGEN shares. Berenberg Bank set a $45.50 target price on shares of Qiagen and gave the stock a “hold” rating in a report on Tuesday, July 14th. Stifel Nicolaus set a $40.00 target price on shares of Qiagen in a research report on Friday, August 7th. Barclays set a $40.00 price target on shares of Qiagen and gave the company an “equal weight” rating in a research note on Friday, August 7th. DZ Bank cut shares of Qiagen from a “strong-buy” rating to a “hold” rating in a research report on Thursday. Finally, Morgan Stanley reissued an “overweight” rating on shares of Qiagen in a research report on Friday, September 11th. Four investment analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $44.43.
Get Our Latest Analysis on Qiagen
Qiagen Stock Performance
Shares of NYSE QGEN opened at $50.42 on Friday. The stock has a 50 day moving average price of $44.44 and a 200 day moving average price of $40.64. Qiagen has a 52 week low of $32.53 and a 52 week high of $57.81. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.31 and a current ratio of 2.85. The stock has a market capitalization of $10.39 billion, a PE ratio of 25.83, a price-to-earnings-growth ratio of 5.01 and a beta of 0.61.
Qiagen (NYSE:QGEN – Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.62 earnings per share for the quarter, topping the consensus estimate of $0.60 by $0.02. Qiagen had a return on equity of 14.47% and a net margin of 19.49%. The firm had revenue of $535.04 million for the quarter, compared to analyst estimates of $527.50 million. During the same quarter in the previous year, the firm earned $0.60 EPS. The business’s quarterly revenue was up .2% on a year-over-year basis. Qiagen has set its FY 2026 guidance at 2.430- EPS. Analysts predict that Qiagen will post 2.44 earnings per share for the current fiscal year.
More Qiagen News
Here are the key news stories impacting Qiagen this week:
- Positive Sentiment: Qiagen updated third-quarter 2026 guidance to adjusted EPS of $0.65 and revenue of $548 million, above consensus estimates of $0.62 and $534.1 million, respectively. The figures are consistent with the company’s preliminary results and signal better-than-expected operating performance.
- Positive Sentiment: EQT agreed to acquire Qiagen in an all-cash transaction valued at approximately $12.1 billion, offering €46.50 per share. The takeover provides a defined valuation and has been unanimously accepted, with the transaction nearing completion. Qiagen to Be Acquired by EQT for $12.1 Billion in All-Cash Deal
- Positive Sentiment: Robert W. Baird raised its price target to $52 from $50 and upgraded the stock to “outperform,” citing potential value near the takeover consideration. Robert W. Baird Qiagen rating
- Neutral Sentiment: Unusually heavy call-option activity suggests increased short-term trading interest, with call purchases roughly doubling typical volume, but it does not establish a fundamental change in valuation.
- Neutral Sentiment: JPMorgan reaffirmed its “neutral” rating while lowering its price target to $52 from $55, leaving limited projected upside relative to the current trading level. JPMorgan Qiagen rating
- Negative Sentiment: Law firms Brodsky & Smith and Halper Sadeh announced investigations into whether Qiagen obtained a fair price for shareholders. Such reviews could create deal uncertainty, although they do not currently indicate that the transaction will be blocked. Brodsky & Smith shareholder investigation
About Qiagen
QIAGEN N.V. (NYSE:QGEN) is a global provider of sample preparation technologies, molecular testing solutions and bioinformatics for the life sciences and molecular diagnostics markets. The company develops products that help researchers and clinical laboratories isolate, analyze and interpret DNA, RNA and other biological materials.
Its portfolio includes sample collection and purification kits, automated laboratory instruments, PCR and next-generation sequencing assays, digital PCR solutions, bioinformatics software and related consumables.
Read More
- Five stocks we like better than Qiagen
- Market Volatility Playbook: Trade the Noise, Get Paid to Ignore the Rest
- Bloom Energy Just Reported—Its Biggest Order Is Still Waiting on a Pipeline
- Why Western Digital’s AI Storage Boom Defies the Chip Sell-Off
- Grand Canyon Education Strengthens Its Outlook, But Wall Street Remains Divided
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.
